Morgan Stanley Aeterna Zentaris Inc. Transaction History

Morgan Stanley

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Oct 27, 2022	BUY	$0.17 - $0.37 $41,922 - $91,242	246,600 Added 440.36%	302,600 $59,000
Q2 2022 Aug 15, 2022	BUY	$0.17 - $0.37 $41,922 - $91,242	246,600 Added 440.36%	302,600 $59,000
Q1 2022 Oct 27, 2022	SELL	$0.33 - $0.42 $81,378 - $103,572	-246,600 Reduced 81.49%	56,000 $20,000
Q1 2022 May 13, 2022	BUY	$0.33 - $0.42 $11,326 - $14,416	34,324 Added 158.35%	56,000 $20,000
Q4 2021 Feb 14, 2022	SELL	$0.36 - $0.77 $1,484 - $3,175	-4,124 Reduced 15.98%	21,676 $7,000
Q3 2021 Nov 15, 2021	BUY	$0.59 - $0.88 $15,222 - $22,704	25,800 New	25,800 $19,000

Ticker AEZS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 4,855,880
Market Cap $19.4M
Description
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult grow...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.